Fundraising Overview - The company, Hangzhou Anxu Biotechnology Co., Ltd., successfully raised a total of RMB 1,200.30 million by issuing 15,333,400 shares at a price of RMB 78.28 per share, with a net amount of RMB 1,055.85 million after deducting various fees [1] - The funds have been deposited into a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the bank [1] Fund Management - The company has established a fundraising management system in accordance with regulatory requirements to ensure effective use and management of the raised funds [2] - Strict approval processes are in place for the use of funds, ensuring that they are used for designated projects [2] Supervision Agreements - Multiple tripartite and quadripartite supervision agreements have been signed with various banks to regulate the management of the raised funds, with all agreements functioning normally as of December 31, 2024 [3][4][5] Account Closure - Due to the completion of certain fundraising projects, the company has decided to close specific fundraising accounts to streamline management and reduce costs [5] - The closure of these accounts has been completed, and the corresponding supervision agreements have been terminated [5]
杭州安旭生物科技股份有限公司关于部分募集资金账户注销的公告